Juncell Therapeutics to Present Preclinical Data on Innovative Pretreatment Regimen of TIL Therapy at AACR Annual Meeting 2025

Juncell Therapeutics to Present Preclinical Data on Innovative Pretreatment Regimen of TIL Therapy at AACR Annual Meeting 2025

SHANGHAI, March 26, 2025 /PRNewswire/ -- Shanghai Juncell Therapeutics Co., Ltd. (Juncell Therapeutics), a clinical-stage biotech developing innovative IL-2-independent Tumor-Infiltrating Lymphocyte (TIL) therapies for cancers, announced that a...

menu
menu